Skip to main content

6 Result(s)

within J A Woyach Remove this filter

and

  1. No Access

    Article

    PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment

    D Jones, J A Woyach, W Zhao, S Caruthers, H Tu, J Coleman, J C Byrd… in Leukemia (2017)

  2. No Access

    Article

    Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

    The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins, including tumor suppressors, and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), a...

    Z A Hing, H Y J Fung, P Ranganathan, S Mitchell, D El-Gamal, J A Woyach… in Leukemia (2016)

  3. No Access

    Article

    Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia

    Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AICs). Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of relapsed...

    K A Rogers, A S Ruppert, A Bingman, L A Andritsos, F T Awan, K A Blum… in Leukemia (2016)

  4. No Access

    Article

    Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

    J A Woyach, G Lozanski, A S Ruppert, A Lozanski, K A Blum, J A Jones, J M Flynn… in Leukemia (2012)

  5. No Access

    Article

    Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol

    Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis t...

    K A Blum, A S Ruppert, J A Woyach, J A Jones, L Andritsos, J M Flynn, B Rovin… in Leukemia (2011)

  6. No Access

    Article

    A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma

    Rituximab has modest activity in relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma but is associated with tumor necrosis factor-α (TNF-α) release that can cause CLL proliferation and inhib...

    J A Woyach, T S Lin, M S Lucas, N Heerema, M E Moran, C Cheney, D M Lucas… in Leukemia (2009)